REPLIGEN CORP Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
REPLIGEN CORP (RGEN) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of -$1.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-02-26
- REPLIGEN CORP effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was -$1.29M.
- REPLIGEN CORP effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$805.00K, a 587.88% decline from fiscal 2023.
- REPLIGEN CORP effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $165.00K, a 29.49% decline from fiscal 2022.
- REPLIGEN CORP effective income tax rate reconciliation, tax contingency, amount for fiscal 2022 was $234.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | -$1.29M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$805.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $165.00K 10-K · filed 2026-02-26 |
| 2022-12-31 | $234.00K 10-K · filed 2025-03-14 |
| 2021-12-31 | -$443.00K 10-K/A · filed 2024-11-18 |
| 2020-12-31 | -$168.00K 10-K · filed 2023-02-22 |
| 2019-12-31 | $1.07M 10-K · filed 2022-02-17 |
| 2018-12-31 | $1.02M 10-K · filed 2021-02-24 |
| 2017-12-31 | $241.00K 10-K · filed 2020-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |